Lee Golden, M.D., Chairman, Advisory Board
Dr. Golden is currently SVP and Chief Medical Officier at PTC Therapeutics Inc. Previously he was Chief Medical Officer at Gemphire (NASDAQ:GEMP), a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, including dyslipidemia and NASH. Prior to that, he served as Senior VP, Therapeutic Business Unit Head for Cardiovascular, Pulmonary, and Central Nervous System at Mesoblast (NASDAQ:MESO). Dr. Golden is an expert in the oversight of large cardiovascular trials and the development of new cardiovascular/blood therapeutics. He has served as Executive Director of Neuroscience and Ophthalmology at Novartis Pharmaceuticals, Cardiovascular Executive Director at Eisai Medical Research, and Cardiovascular Team Leader/Medical Director at Pfizer Pharmaceuticals. Dr. Golden has managed global cross-functional teams responsible for creating and implementing strategic development and commercial plans. Dr. Golden is a graduate of New York University School of Medicine and is formally trained as an Interventional Cardiologist.
Michael D. Webb, MA, MBA, Advisory Board Member
Michael D. Webb, MA, MBA has more than 25 years of entrepreneurial and senior leadership experience in healthcare and the life sciences. He specializes in early-stage companies focused on targeted therapeutics and molecular diagnostics. Currently, Mike is President and CEO of CXL Ophthalmics, LLC. He has been a founder and CEO of several biotechnology companies taking them from seed funding through venture financing and NASDAQ IPO. Mike began his career in Booz, Allen, and Hamilton’s Chicago office, specializing in healthcare and life sciences and subsequently at CIBA-Geigy (now Novartis) where he was last a senior vice president. Mike holds Bachelor’s degrees in Biochemistry and Economics from the University of Kansas, summa cum laude, and an MA in International Relations from Sussex University in the UK, completing his thesis on “Pharmaceuticals Policy and the World Health Organization”. In addition, he holds an MBA degree from Kellogg with a concentration in healthcare management. He is a past Chairman of the Massachusetts Biotechnology Council.
Maureane R. Hoffman, M.D., Ph.D., Advisory Board Member
Dr. Hoffman is a tenured Professor of Pathology at Duke, and Director of the Hematology, Transfusion Service, and Clinical Chemistry Laboratories at the Durham VA Medical Center. Dr. Hoffman’s research focuses on the role of cellular features in controlling hemostasis and thrombosis. Her work in collaboration with Dr. Harold Roberts and others has led to the development of an in-vitro cell-based model that mimics many aspects of hemostasis in-vivo. She has authored or co-authored over 115 journal articles and has lectured extensively on the laboratory aspects of coagulation.